

Adamis Pharmaceuticals Corporation

01:20 18 Jan 2019

Adamis Pharma's stock soars after commercial partner launches Epi pen alternative in the US

Shares in Adamis Pharmaceuticals Corp (NASDAQ:ADMP) soared Thursday after the biotech said its partner Sandoz Inc launched a SYMJJEPI (epinephrine) 0.3 mg injection in the United States for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.

Sandoz is launching the medicine as an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors. The Symjepi injector is a competitor of Mylan NV's (NASDAQ:MYL) well-known EpiPen product.

Adamis stock shot up 9.13% to \$2.87 in the premarket trading session.

READ: Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product
SYMJEPI will be rolled out via a phased launch and will initially be available in the institutional setting, an established channel where Sandoz has significant experience followed by a rollout in the retail market. Sandoz will distribute and sell the 0.3 and 0.15 mg versions of Symjepi, said Adamis.

"Both Symjepi 0.3 mg and Symjepi 0.15 mg products stem from Adamis' commitment to develop and provide high quality, affordable treatment options to patients. With recent news of epinephrine product shortages in the US, we worked together with Sandoz in getting this potentially life-saving quality product into the market," said Adamis Pharmaceuticals CEO Dennis J Carlo.

The CEO said Adamis was excited to work with Sandoz and expected a successful launch.

San Diego, California-based Adamis Pharmaceuticals is a specialty biotech focused on developing products for tackling respiratory disease and allergy.

It is also developing a sublingual tadalafil product for the treatment of erectile dysfunction, a naloxone injection for treating an opioid overdose, and a metered dose inhaler and dry powder inhaler for helping asthma patients.


Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Price: US\$1.17

Market Cap: US\$55.74M

1 Year Share Price Graph



Share Information

Code: ADMP

Listing: NASDAQ

52 week	High	Low
	\$4.25	\$1.17

Sector: Pharmaceuticals

Website:
www.adamispharmaceuticals.com

Company Synopsis:

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15 mg products were approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Author:
Proactive Investors Australia
+61 (0)2 9280 0700
action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.